期刊文献+

蛋白精氨酸甲基转移酶5抑制剂研究进展 被引量:1

Research progress of protein arginine methyltransferase 5 inhibitors
下载PDF
导出
摘要 蛋白精氨酸甲基转移酶(PRMTs)对组蛋白和非组蛋白的翻译后修饰在生物学过程中起到了非常重要的作用。PRMT5是精氨酸残基对称双甲基化的主要酶,已被视为肿瘤治疗的潜在靶点。在过去10年中,发现和开发PRMT5抑制剂已经成为科研人员关注的热点。本文介绍了PRMT5的结构、生化功能以及其与肿瘤的相关性,同时就目前在研的PRMT5抑制剂与其结合方式以及生物活性进行综述,并讨论了PRMT5抑制剂在肿瘤治疗中的应用潜力。 Protein arginine methyltransferases,which proceed the post-translational modification of both his-tones and non-histones,play an important role in many biological pathways.Protein arginine methyltransferase 5(PRMT5)is a major enzyme responsible for symmetric di-methylation of arginine residues and has been suggestedas a potential therapeutic target for tumors.In the past decade,the discovery and development of PRMT5 inhibi-tors have become one of the most important research fields.This article introduces the structure and biochemicalfunction of PRMT5 and its correlation with cancer reviews,the binding modes and biological data of PRMT5 inhibitors under development,and discusses the clinical application potential of PRMT5 inhibitors in the treat-ment of cancer.
作者 詹康宁 全旭 黄张建 赵立文 ZHAN Kangning;QUAN Xu;HUANG Zhangjian;ZHAO Liwen(Center of Drug Discovery,China Pharmaceutical University,Nanjing 210009;Nanjing Sanhome Pharmaceutical Co.,Ltd.,Nanjing 210038,China)
出处 《中国药科大学学报》 CAS CSCD 北大核心 2021年第3期371-378,共8页 Journal of China Pharmaceutical University
关键词 蛋白精氨酸甲基转移酶5 小分子抑制剂 表观遗传 精氨酸甲基化 抗肿瘤靶点 PRMT5 small molecular inhibitors epigenetics arginine methylation antitumor target
  • 相关文献

参考文献1

二级参考文献50

  • 1Shorter J, Warren G. Golgi architecture and inheritance. Annu Rev Cell Dev Biol2002; 18:379-420.
  • 2Colanzi A, Suetterlin C, Malhotra V. Cell-cycle-specific Golgi fragmentation: how and why? Curr Opin Cell Biol 2003; 15:462-467.
  • 3Barr FA, Short B. Golgins in the structure and dynamics of the Golgi apparatus. Curr Opin Ceil Biol2003 ; 15:405-413.
  • 4Ramirez IB, Lowe M. Golgins and GRASPs: holding the Golgi together. Semin Cell Dev Biol2009; 20:770-779.
  • 5Nakamura N, Rabouille C, Watson R, et al. Characterization of a cis-Golgi matrix protein, GM130. Y Cell Biol 1995; 131:1715-1726.
  • 6Nakamura N, Lowe M, Levine TP, Rabouille C, Warren G. The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner. Cell 1997; 89:445-455.
  • 7Marra P, Maffucci T, Daniele T, et al. The GM130 and GRASP65 Golgi proteins cycle through and define a subdo- main of the intermediate compartment. Nat Cell Biol 2001; 3:1101-1113.
  • 8Sonnichsen B, Lowe M, Levine T, et al. A role for giantin in docking COPI vesicles to Golgi membranes. J Cell Biol 1998; 140:1013-1021.
  • 9Beard M, Satoh A, Shorter J, Warren G. A cryptic Rablbinding site in the pl 15 tethering protein. J Biol Chem 2005; 280:25840-25848.
  • 10Puthenveedu MA, Bachert C, Puri S, Lanni F, Linstedt AD. GM130 and GRASP65-dependent lateral cisternal fusion allows uniform Golgi-enzyme distribution. Nat Cell Biol 2006; 8:238-248.

共引文献15

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部